MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/kez071

Медицинская библиотека · Rheumatology (Oxford, England) · 2019

Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients.

Durel Cécile-Audrey, Hot Arnaud, Trefond Ludovic, Aumaitre Olivier, Pugnet Gregory, Samson Maxime, Abad Sébastien, Belot Alexandre, Blanchard-Delaunay Claire, Cohen Pascal, Cohen-Aubard Fleur, Cottin Vincent, Crestani Bruno, Moreuil Claire De, Durupt Stéphane, Garzaro Margaux, Girszyn Nicolas, Godeau Bertrand, Hachulla Eric, Jamilloux Yvan, Jego Patrick, Killian Martin, Lazaro Estibaliz, Le Gallou Thomas, Liozon Eric, Martin Thierry, Papo Thomas, Perlat Antoinette, Pillet Pascal, Guillevin Loïc, Terrier Benjamin

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

Orbital mass is a rare and sight-threatening manifestation of ANCA-associated vasculitides, which remains a therapeutic challenge. We aimed to describe the presentation, therapeutic management and outcome of ANCA-associated vasculitides-related orbital mass.

METHODS

We conducted a French nationwide retrospective study of patients with orbital mass in the setting of ANCA-associated vasculitides according to ACR criteria and/or Chapel Hill Consensus Conference definitions.

RESULTS

Fifty-nine patients [33 women, median age 46 (range 7-90) years] were included. Fifty-six (95%) patients had granulomatosis with polyangiitis, two eosinophilic granulomatosis with polyangiitis and one microscopic polyangiitis. Orbital mass was unilateral in 47 (80%) cases, and seemed to develop from ENT involvement in most cases. Orbital mass biopsy was available in 32 (54%) patients, showing lymphoplasmacytic infiltration in 65%, fibrosis in 55%, granulomas in 48% and vasculitis in 36%. All patients but one received glucocorticoids as first-line therapy associated with immunosuppressive agents in 82%, mainly cyclophosphamide. Response to therapy was noted in 52% of patients treated with cyclophosphamide compared with 91% of those treated with rituximab. Twenty-seven (46%) patients required a second-line therapy because of relapse (59%) or refractory course (41%). Sequelae included visual impairment in 28%, with definitive blindness in 17%. Refractory course was associated with PR3-ANCA positivity, visual loss and contiguous pachymeningitis.

CONCLUSION

Orbital mass is associated with refractory course and high frequency of sequelae, especially blindness. Refractory course is associated with PR3-ANCA positivity, visual loss and contiguous pachymeningitis.

Для цитирования: Durel Cécile-Audrey, Hot Arnaud, Trefond Ludovic, Aumaitre Olivier, Pugnet Gregory, Samson Maxime, Abad Sébastien, Belot Alexandre, Blanchard-Delaunay Claire, Cohen Pascal, Cohen-Aubard Fleur, Cottin Vincent, Crestani Bruno, Moreuil Claire De, Durupt Stéphane, Garzaro Margaux, Girszyn Nicolas, Godeau Bertrand, Hachulla Eric, Jamilloux Yvan, Jego Patrick, Killian Martin, Lazaro Estibaliz, Le Gallou Thomas, Liozon Eric, Martin Thierry, Papo Thomas, Perlat Antoinette, Pillet Pascal, Guillevin Loïc, Terrier Benjamin. Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients.. Rheumatology (Oxford, England). 2019. DOI: 10.1093/rheumatology/kez071.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.